Research programme: small molecule and peptide therapeutics - Enzo Biochem

Drug Profile

Research programme: small molecule and peptide therapeutics - Enzo Biochem

Latest Information Update: 03 Nov 2015

Price : $50

At a glance

  • Originator Enzo Biochem
  • Class Peptides; Small molecules
  • Mechanism of Action LDL receptor modulators; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bone disorders; Diabetes mellitus; Osteonecrosis; Osteoporosis

Most Recent Events

  • 21 Sep 2015 Preclinical trials in Osteonecrosis in USA (PO) prior to September 2015
  • 21 Sep 2015 Preclinical trials in Osteoporosis in USA (PO) prior to September 2015
  • 14 Oct 2009 Preclinical in Diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top